Manipal Hospital Yeshwanthpur Leads the Charge as Heart Attacks in Young Indians Reach Crisis Levels
Striking recent investigations into sudden cardiac arrests and deaths in Hassan District, Karnataka, confirm that one-third of these fatalities were among auto and cab drivers—a profession increasingly recognized as highly vulnerable due to, long hours, erratic schedules, and hazardous environmental exposures. This stark reality has highlighted the need for proactive heart health education and life-saving interventions for communities at risk, especially transport workers who spend most of their day on the road.
In this context, CPR (Cardiopulmonary Resuscitation) training has never been more critical. During a sudden cardiac arrest episode, administering immediate CPR can dramatically increase the victim's chance of survival while they await emergency care. Immediate intervention keeps blood and hope flowing until professional help arrives, making every trained community member a potential lifesaver.
CPR Awareness Drive: A Step Toward Safer Streets: In response to this urgent public health need, Manipal Hospital Yeshwanthpur organized a CPR demonstration and heart health awareness session for over 20 auto rickshaw drivers, led by Mr. Rudramurthy, General Secretary of the Auto Rickshaw Drivers' Union (ARDU). Guided by Dr Prasanna Katti, Senior Consultant – Interventional Cardiology and Dr. Eshwari Devi, Registrar, Cardiology, at Manipal Hospital Yeshwanthpur, the event aimed to equip participants with tangible, life-saving skills.
The session included practical demonstrations using adult male, female, and infant (baby) mannequins, ensuring that participants were equipped to perform CPR on individuals of any age or gender during real-life emergencies. Speaking on the significance of hands-on demonstration, Dr. Eshwari Devi stated, 'Learning to perform a CPR and helping a person in a critical condition makes a huge difference in saving a life. Every individual or the first responder trained in CPR becomes a potential hero and a lifesaver for the community.'
In a move to strengthen emergency response readiness, both doctors not only presided over the event and led CPR training but also personally distributed and affixed Manipal SOS – QR Code stickers to each participant's auto rickshaw. The SOS QR code is Manipal Hospitals innovative technology that enables the first-responder or caregiver to seek swift ambulance support during emergencies by simply scanning the QR code, which is equipped with precise location detection. This ensures that the victim receives care within the critical 'Golden Hour'—a move that can make all the difference in survival outcomes.
Equipping the participants with further knowledge on general health, wellness, and heart health in particular, Dr. Katti shared health tips tailored for the demanding routines of auto drivers. He discussed the dangers of smoking, the importance of regular physical activity, a balanced diet, and recognizing early signs of heart trouble. 'Quit smoking and drinking, also exercise regularly to prevent the chances of a heart attack. Everybody must learn CPR and try their best to save someone who is having a heart attack,' he stated.
Through this initiative, Manipal Hospital Yeshwanthpur, reaffirms its commitment to preventive care, community outreach, and empowering everyday heroes with the knowledge and skills that can save lives. Manipal Hospitals continues to lead the charge in making advanced cardiac care more accessible, not just inside hospital walls, but out in the community where it matters most.
For more information, please visit: https://www.manipalhospitals.com/
Photo: https://mma.prnewswire.com/media/2733288/MANIPAL_CPR_Awareness_1.jpgPhoto: https://mma.prnewswire.com/media/2733289/MANIPAL_CPR_Awareness_2.jpg
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Malaysian Reserve
8 hours ago
- Malaysian Reserve
Medunik USA expands Siklos® (hydroxyurea) coverage under Medicaid Programs to 37 states
PRINCETON, N.J., July 22, 2025 /PRNewswire/ – Medunik USA, a specialty pharmaceutical company dedicated to providing rare disease patients with access to orphan drugs and part of Duchesnay Pharmaceutical Group (DPG), winner of the 2024 Life Sciences Innovation Award by ADRIQ, is pleased to announce that public reimbursement for Siklos® (hydroxyurea) under Medicaid Programs is now available in 37 states, with 13 states including it on their Preferred Drug List, while 24 states offer it with limited, or no, restrictions. This important milestone for Medunik USA allows broader access to this essential medicine, benefiting patients suffering from sickle cell disease (SCD). Siklos® has been used worldwide to treat SCD for over 15 years and was approved by the FDA for use in the USA in 2017. This medicine is the only hydroxyurea (HU)-based therapeutic option that offers both flexible dosing and administration, giving patients and caregivers more control over managing their care and shaping a treatment routine that works for them. Patients can choose the best way to take Siklos®, whether by swallowing it whole or split based on the dose, or dissolving it in a small amount of water. Siklos® is the only FDA-approved dissolvable formulation of hydroxyurea that reduces painful crises and blood transfusions for sickle cell patients aged 2 years and older. Siklos® has a BOXED WARNING regarding Low Blood Cell Count and Cancer. The most common side effects of Siklos® in children include: infections and low white blood cells, and in adults include: infections, headache, and dry skin. 'We are proud to see increased coverage for this important therapy, which represents a significant step forward in the standard of care for patients with sickle cell disease. Siklos® provides patients with options on how to best take their HU treatment,' said Tanya Carro, Executive Vice President, U.S. Entities. 'With fewer SCD treatment options currently available, it is even more important to empower patients to stay on therapy in a way that fits their lives. That's what drives long-term adherence and meaningful health outcomes.' Sickle cell anemia is the most common inherited blood disorder, resulting in the production of abnormal hemoglobin, known as hemoglobin-S, responsible for the sickling of red blood cells. This disease affects nearly 100,000 Americans, decreases life expectancy by 25 to 30 years, induces significant morbidity and, may therefore, reduce quality of life1,2. Most of those affected are of African ancestry; a minority are of Hispanic or southern European, Middle Eastern or Asian Indian descent3. Committed to improving the lives of people living with rare disorders, Medunik USA strives to remove the logistical barriers and to broaden reimbursement pathways to empower patients with SCD and their caregivers. Medunik USA supports patient access by offering a robust assistance program that includes educational resources and savings programs. For more information please visit: . INDICATION AND IMPORTANT SAFETY INFORMATION SIKLOS is a prescription medicine that is used to reduce the frequency of painful crises and reduce the need for blood transfusions in adults and children, 2 years of age and older, with sickle cell anemia with recurrent moderate to severe painful crises. It is not known if SIKLOS is safe and effective in children less than 2 years of age. IMPORTANT SAFETY INFORMATION BOXED WARNING: LOW BLOOD CELL COUNT and CANCERSee Full Prescribing Information for complete Boxed Warning. Low blood cell counts are common with SIKLOS, including low red blood cells, white blood cells, and platelets, and can be severe and life threatening. If your white blood cell count becomes very low, you are at increased risk for infection. Your healthcare provider will check your blood cell counts before and every 2 weeks during treatment with SIKLOS. Your healthcare provider may change your dose or tell you to stop taking SIKLOS if you have low blood cell counts. Tell your healthcare provider right away if you get any of the following symptoms: fever or chills; shortness of breath; body aches; unusual headache; feeling very tired; bleeding or unexplained bruising. Cancer. Some people have developed cancer, such as leukemia and skin cancer, after taking SIKLOS for a long time. Your healthcare provider will check you for cancer. You should protect your skin from the sun using sunblock, hats, and sun-protective clothing. WHAT IS THE MOST IMPORTANT INFORMATION YOU SHOULD KNOW ABOUT SIKLOS? SIKLOS can harm your unborn baby. For females taking SIKLOS who can become pregnant: You should talk with your healthcare provider about the risks of SIKLOS to your unborn baby. You should use effective birth control during treatment with SIKLOS and for at least 6 months after treatment with SIKLOS. Your healthcare provider will perform a pregnancy test before you start treatment with SIKLOS. Tell your healthcare provider right away if you become pregnant or think you may be pregnant. For males taking SIKLOS: SIKLOS can affect your sperm. If you have a female sexual partner who can become pregnant, you should use effective birth control during treatment with SIKLOS and for at least 6 months after treatment. SIKLOS may cause fertility problems in males. Talk to your healthcare provider if this is a concern for you. You should talk with your healthcare provider about the risks of SIKLOS to your unborn baby. You should use effective birth control during treatment with SIKLOS and for at least 6 months after treatment with SIKLOS. Your healthcare provider will perform a pregnancy test before you start treatment with SIKLOS. Tell your healthcare provider right away if you become pregnant or think you may be pregnant. WHO SHOULD NOT TAKE SIKLOSDo not take SIKLOS if you are allergic to hydroxyurea or any of the ingredients in SIKLOS. See the Medication Guide for a list of the ingredients in SIKLOS. WHAT SHOULD YOU TELL YOUR HEALTH CARE PROVIDER BEFORE TAKING SIKLOS?Tell your healthcare provider about all of your medical conditions, including if you: have kidney problems or are receiving hemodialysis have liver problems have human immunodeficiency virus (HIV) or take HIV medicines. Taking SIKLOS with certain HIV medicines can cause serious reactions and may lead to death. have increased levels of uric acid in your blood (hyperuricemia) have a history of receiving interferon therapy or are currently receiving interferon therapy have leg wounds or ulcers plan to receive any vaccinations. You should not receive 'live vaccines' during treatment with SIKLOS. are pregnant or plan to become pregnant. See 'What is the most important information I should know about SIKLOS?' are breastfeeding or plan to breastfeed. It is not known if SIKLOS can pass into your breast milk. Do not breastfeed during treatment with SIKLOS. are using a continuous glucose monitor (CGM) to test your blood glucose. Talk to the healthcare provider that prescribed your CGM about whether it is safe to use while you are taking SIKLOS. Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. WHAT ARE THE POSSIBLE SIDE EFFECTS OF SIKLOS?SIKLOS may cause serious side effects, including: See 'What is the most important information I should know about SIKLOS?' Skin ulcers, including leg ulcers, and death of skin tissue (gangrene) have happened in people who take SIKLOS. This has happened most often in people who receive interferon therapy or have a history of interferon therapy. Your healthcare provider will decrease your dose or stop treatment with SIKLOS if you develop any skin ulcers. Enlarged red blood cells (macrocytosis). Macrocytosis is common in people who take SIKLOS and can make it difficult to detect a decrease of folic acid. Your healthcare provider may prescribe a folic acid supplement for you. Hemolytic Anemia, the fast breakdown of red blood cells, has happened in people who take SIKLOS. Tell your healthcare provider I you develop yellowing of your skin (jaundice) or blood in your urine. Your healthcare provider may do blood tests if you have persistent or worsening anemia not related to sickle cell anemia. The most common side effects of SIKLOS in children include: infections and low white blood cells. The most common side effects of SIKLOS in adults include: infections, headache, and dry skin. These are not all the possible side effects of SIKLOS. You are encouraged to report negative side effects of prescription drugs to the FDA at or 1-800-FDA-1088. Please read the Full Prescribing Information, including Boxed Warning, Medication Guide and Instructions for Use, at ABOUT MEDUNIK USA Based in Princeton, New Jersey, Medunik USA is part of Duchesnay Pharmaceutical Group and works to improve the health and quality of life of Americans living with rare diseases by making orphan drug therapies available in the United States. Through its strategic partnerships, Medunik USA develops and provides Americans suffering from rare disease with access to orphan drugs that are not currently available in the U.S. Medunik USA makes critical medications to treat rare diseases available to American patients who might not otherwise have access to these medications. For more information about Medunik USA, please visit Follow us on LinkedIn. ABOUT DUCHESNAY PHARMACEUTICAL GROUP Duchesnay Pharmaceutical Group (DPG), with its affiliated companies, is headquartered in Blainville, Quebec. The Group consists of six pharmaceutical companies to meet the needs of patients in Canada, the U.S. and abroad. The companies are Duchesnay (Canada) and Duchesnay USA, both dedicated to women's health; Medunik Canada and Medunik USA, which provide treatments for rare and debilitating diseases; and Analog Pharma Canada and Analog Pharma, specializing in orphan generic medications. From its state-of-the-art manufacturing plant, DPG exports its innovative treatments to more than 50 countries. DPG is one of the eight companies across the country chosen to participate in the Government of Canada's Global Hypergrowth Project. This appointment offers exclusive and personalized support for at least two years, in order to accelerate its growth to become an anchor firm in the Canadian economy. DPG is the winner of the 2024 Life Sciences Innovation Award by ADRIQ, the Association for the Development of Research and Innovation of Quebec, which recognizes DPG's healthy workplace culture and commitment to pharmaceutical innovation, while DPG president Éric Gervais is the recipient of the 2024 Bernard-Landry Award by ADRIQ which acknowledges his impactful leadership on Quebec's research and innovation ecosystem. DPG, through its proprietary research and development, and through exclusive partnerships, offers innovative treatments for a variety of medical conditions in women's health, urology, oncology and for rare diseases, plus lower-cost generic medications. DPG recognizes the dedication and professionalism of its employees and promotes a positive culture and flexible work environment. It is deeply committed to environmental responsibility and to giving back to the community through the support of various charitable organizations. For more information, please visit Follow us on LinkedIn. References: 1. Platt OS et al. Mortality in sickle cell disease. Life expectancy and risk factors for early death. The New England Journal of Medicine 330, 1639-1644, doi:10.1056/NEJM199406093302303 (1994). 2. McGann PT and Ware RE, Hydroxyurea therapy for sickle cell anemia. Expert opinion on drug safety 14, 1749-1758, doi:10.1517/14740338.2015.1088827 (2015). 3. National Heart, Lung, and Blood Institute, National Institutes of Health, Sickle Cell Disease,
Malaysian Reserve
a day ago
- Malaysian Reserve
Swoop Appoints Sara Michael as EVP of Content at MyHealthTeam
NEW YORK, July 21, 2025 /PRNewswire/ — Swoop, a leader in AI-driven, data-powered, and privacy-compliant omnichannel healthcare marketing, today announced the appointment of Sara Michael as Executive Vice President of Content at MyHealthTeam, reinforcing the company's commitment to delivering trusted, medically verified information and meaningful engagement for people living with chronic and rare conditions. A seasoned leader in health journalism and digital content strategy, Sara most recently served at Dotdash Meredith, where she led editorial and business strategy for health brands including Verywell Health, Verywell Mind, and She brings deep expertise in developing high-impact content experiences that prioritize patient needs while aligning with business growth. Sara will lead a unified content organization spanning editorial development, design, video, content operations, and copy editing. Her leadership is instrumental in scaling MyHealthTeam's reach, quality, and impact as the largest opt-in patient community in the U.S., now spanning more than 60 condition-specific social networks. 'I've long admired the mission and impact of MyHealthTeam. I'm thrilled to join at such an exciting time, alongside such a passionate team, all focused on supporting people living with chronic conditions,' said Sara. 'This role brings together my passion for health journalism and innovation with a mission that truly matters — empowering people to take control of their health by connecting with others and accessing reliable information they can trust.' As EVP of Content, Sara will drive initiatives to: Expand the reach and depth of content across all MyHealthTeam platforms Integrate medically reviewed education and patient insights into all engagement Elevate storytelling to reflect the diverse experiences of chronic condition communities Enable brand partners to deliver relevant, privacy-safe messages that align with patient needs 'Sara's arrival marks a major step forward in scaling our patient-first model,' said Eric Peacock, Chief Patient Officer of Swoop and Co-founder and President of MyHealthTeam. 'Her leadership will accelerate our ability to deliver authentic, high-quality content at scale — meeting patients where they are, while ensuring our brand partners can engage in ways that are respectful, useful, and effective.' About SwoopSwoop is a leading provider of AI-driven, precision healthcare omnichannel solutions dedicated to protecting consumer privacy and improving patient outcomes. By prioritizing privacy and compliance, Swoop delivers industry-leading audience segments, 100% MLR-approved conversational AI agents, and now a leading opted-in patient social network in the U.S. through its acquisition of MyHealthTeam. Swoop's solutions drive meaningful patient and provider engagement, optimal conversion, and measurable increases in Rx lift across the patient health journey. About MyHealthTeamMyHealthTeam, a Swoop company, is the creator of one of the largest and highly engaged patient social networks in healthcare, offering more than 62 condition-specific communities to support patients with chronic and rare conditions. These platforms empower millions of opted-in patients nationwide to connect, share resources, and access medically verified information to better manage their health.
Malaysian Reserve
4 days ago
- Malaysian Reserve
Wendy Luk Launches Soul Mission Alignment Program to Guide Spiritually Minded Professionals Into Their Higher Calling
An eight-week spiritual purpose coaching program that blends quantum healing, intuitive guidance, soul activations for Lightworkers, Starseeds, and mission-driven professionals ready to align with their Divine path VANCOUVER, BC, July 18, 2025 /PRNewswire/ — Renowned Intuitive Quantum Healer and Soul Mission Coach Wendy Luk is proud to announce the official launch of her Soul Mission Alignment Program, an eight-week transformational experience premiering on September 9, 2025. The program is designed for Lightworkers, Starseeds, spiritually minded and purpose-driven professionals seeking clarity, healing, and purpose alignment to step fully into their soul-led mission. Developed through Wendy's personal healing journey and years of work with spiritually conscious clients, the Soul Mission Alignment Program offers a unique combination of quantum healing, soul activations, and structured spiritual coaching. The program's step-by-step framework supports participants in shedding outdated identities, releasing unconscious limitations, and activating their highest potential. 'This program is designed for those who feel stuck, disconnected, or unfulfilled and are seeking clarity and alignment with their higher calling,' said Wendy Luk. 'Through this journey, participants will not only heal on a soul level but also gain the tools and confidence to live a life of their true aspirations and create a positive impact in the world.' Each week of the program focuses on a specific energetic or spiritual layer of healing, culminating in the creation of a personalized Soul Mission Statement. Participants will walk away with a crystal-clear purpose, access to their Divine gifts, and a higher vibrational path forward rooted in authenticity, confidence, and service. The spiritual self-development sector has experienced significant growth, with the Global Wellness Institute reporting a 6.5% annual increase in demand for this sector. Programs like Soul Mission Alignment meet a growing need for one's soul mission and activating Divine Purpose in both personal and professional life. Enrollment is now open, with limited spots available to preserve the intimate, community-based program structure. Join the Soul Mission Alignment Program, register now at or About Wendy Luk Wendy Luk is an Intuitive Quantum Healer and Spiritual Coach dedicated to helping Lightworkers, Starseeds, and heart-centred professionals reconnect with their true essence and step into their Soul Missions. Through coaching, healing, and soul activations, she guides clients to release limiting patterns and embody their Divine purpose. Photo: Media Contact: wendy@
